{"id":"95dbafed-edd9-5632-af61-53b7fbe8ef5d","stable_key":"cfa4bd86-d88d-555a-975c-68877bf00e0f:lutein-areds-replacement-neovascular","predicate":"associated_with_lower","statement":"The corresponding neovascular-AMD HR was 0.78 (95% CI 0.64–0.94).","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"5d665d64-b6c8-5d0c-a31a-84ddb316165d","mechanism_event_label":"The subtype result favored the pair for neovascular AMD.","subject":{"id":"4c74b110-d9a4-5499-9fb3-9ce735e91937","slug":"areds2-lz-beta-replacement","display_name":"AREDS2 lutein/zeaxanthin versus beta-carotene comparison","entity_type_key":"chemical_species"},"object":{"id":"70b0d6d4-5ba7-55e8-9dc3-9cab8164cd9d","slug":"human-neovascular-amd-progression","display_name":"Progression to neovascular age-related macular degeneration","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"5d665d64-b6c8-5d0c-a31a-84ddb316165d","stable_key":"cfa4bd86-d88d-555a-975c-68877bf00e0f:lutein-areds-replacement-neovascular-event","event_type":"observed_intervention","label":"The subtype result favored the pair for neovascular AMD.","description":"The corresponding neovascular-AMD HR was 0.78 (95% CI 0.64–0.94).","status":"provisional","compartment":null,"participants":[{"entity":{"id":"5dd84367-3f8e-5a3f-b952-a96174ea51fa","slug":"lutein","display_name":"Lutein","entity_type_key":"small_molecule"},"role":"combination_component","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"0a60c685-7502-5ece-9da2-2c1a2e3bcdf1","slug":"zeaxanthin","display_name":"Dietary (3R,3-prime-R)-zeaxanthin","entity_type_key":"small_molecule"},"role":"combination_component","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"73c24cd4-9ae8-5897-8359-fa4d9e8edecb","slug":"beta-carotene","display_name":"All-trans-beta-carotene","entity_type_key":"small_molecule"},"role":"comparator","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"9f0afdde-1ec1-5c8a-bb5e-f3b2b75f67f6","slug":"copper","display_name":"Copper","entity_type_key":"nutrient_element"},"role":"background_formula","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"4c74b110-d9a4-5499-9fb3-9ce735e91937","slug":"areds2-lz-beta-replacement","display_name":"AREDS2 lutein/zeaxanthin versus beta-carotene comparison","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""},{"entity":{"id":"70b0d6d4-5ba7-55e8-9dc3-9cab8164cd9d","slug":"human-neovascular-amd-progression","display_name":"Progression to neovascular age-related macular degeneration","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":5,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/lutein-research/24310343.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"617cbda47a00c8fc552395a255003b013afa72aca6640c5c2e49d2b4caf09a72\", \"start_char\": 0, \"end_char\": 2419, \"text_sha256\": \"617cbda47a00c8fc552395a255003b013afa72aca6640c5c2e49d2b4caf09a72\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Exploratory secondary analyses of AREDS2","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"L+Z 10/2 mg; direct comparison with beta-carotene on AREDS background","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Exploratory contrasts and different confidence thresholds do not contradict the prespecified primary analysis.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Lutein research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"lutein","display_name":"Lutein","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Same AREDS2 cohort, not an independent replication","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The subtype result favored the pair for neovascular AMD.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[lutein-p24310343] Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. (2014). https://pubmed.ncbi.nlm.nih.gov/24310343/ DOI: 10.1001/jamaophthalmol.2013.7376","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Late AMD subtypes","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"084bb4b2-4a34-5f0b-b979-07e2d7318a64","evidence_kind":"source_excerpt","locator":"Lines 762-773","start_line":762,"end_line":773,"excerpt":"### lutein-areds-replacement-neovascular\nThe corresponding neovascular-AMD HR was 0.78 (95% CI 0.64–0.94).\nCondition category: normal\nnutrient_topic: Lutein research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The subtype result favored the pair for neovascular AMD.\norganism: Same AREDS2 cohort, not an independent replication\ntissue_or_cell_type: Late AMD subtypes\nexperimental_model: Exploratory secondary analyses of AREDS2\nlimitations: Exploratory contrasts and different confidence thresholds do not contradict the prespecified primary analysis.\nexposure: L+Z 10/2 mg; direct comparison with beta-carotene on AREDS background\nevidence_span: {\"source_cache\": \"artifacts/lutein-research/24310343.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"617cbda47a00c8fc552395a255003b013afa72aca6640c5c2e49d2b4caf09a72\", \"start_char\": 0, \"end_char\": 2419, \"text_sha256\": \"617cbda47a00c8fc552395a255003b013afa72aca6640c5c2e49d2b4caf09a72\"}\n[lutein-p24310343] Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. (2014). https://pubmed.ncbi.nlm.nih.gov/24310343/ DOI: 10.1001/jamaophthalmol.2013.7376","model_system":"Exploratory secondary analyses of AREDS2","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [lutein-p24310343] Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. (2014). https://pubmed.ncbi.nlm.nih.gov/24310343/ DOI: 10.1001/jamaophthalmol.2013.7376","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"beef4241-6ebd-5b36-864c-6ef3ed7e61b8","stable_key":"import-cfa4bd86-d88d-555a-975c-68877bf00e0f","title":"Lutein: metabolism, signaling and nutrient connections (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"1514ec459913a7044b4c4e1012ed367bcb918298181ebabd2a9e2ccecd789053","revision_id":"bae2c856-0785-546f-b08f-869318c27f9e","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}